US Patent

US9018192 — Unitary pharmaceutical dosage form

Method of Use · Assigned to Bristol Myers Squibb and Gilead Sciences LLC · Expires 2026-06-13 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a unitary oral dosage form containing efavirenz, emtricitabine, and tenofovir DF in a stabilizing configuration.

USPTO Abstract

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.

Drugs covered by this patent

Sustiva (EFAVIRENZ) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-750`	—	Sustiva

Patent Metadata

Patent number: US9018192
Jurisdiction: US
Classification: Method of Use
Expires: 2026-06-13
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb and Gilead Sciences LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.